AlloVir and Kalaris Therapeutics have announced a merger to support a new anti-VEGF opportunity.
Life sciences company AlloVir, Inc. (NASDAQ: ALVR), based in Watham, Mass. and Palo Alto, California, have announced a merger agreement to combine with Kalaris Therapeutics… Read More »AlloVir and Kalaris Therapeutics have announced a merger to support a new anti-VEGF opportunity.